eClinical Technology and Industy News

Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatmen

Excerpt from the Press Release:

PRINCETON, N.J.–(BUSINESS WIRE)–Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. The collaborative team, led by Dr. Rebecca Powell, Assistant Professor of Medicine (Infectious Diseases), secured an NIH R01 Emergency Award of $2 million dollars to expand this study.

“We are proud to partner with Mount Sinai, which has maintained a leading role in COVID-19 research and innovation. We believe this collaboration will help us deliver a novel intervention to counteract this devastating virus,” said Dr. Viraj Mane, Lactiga’s Co-Founder and Chief Scientific Officer.

To date, preliminary in vitro studies demonstrate full neutralization of SARS-CoV-2 viral components, emphasizing the potential applicability of LCTG-001 to COVID-19 infections. Lactiga has engaged the United States Food and Drug Administration through the Coronavirus Treatment Acceleration Program to optimize its transition from research toward first-in-human clinical testing.

Click the button below to continue reading the Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?